NDA 022501 · Apil
Lo Loestrin Fe
Ethinyl Estradiol, Norethindrone Acetate · Oral
Last checked: Nov 20, 2026Latest source record: Apr 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 21, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
501
113 Phase 3, 20 recruiting
FAERS reports
3,223
812 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC ) use. This risk increases with age , particularly in women over 35 years of age , and with the number of cigarettes smoked . For this reason, COCs should not be used by w omen who are over 35 years of age and smoke [ see Contraindications (4) ] . WARNING : CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See Full Prescribing Information for complete boxed warning. Women over 35 years old who smoke should not use Lo Loestrin Fe ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC ) use ( 4 )
What it is approved for
From the label in effect Mar 7, 2025.
Lo Loestrin ® Fe is indicated for use by women to prevent pregnancy [ see Clinical Studies (14) ] . The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of > 35 kg/m 2 has not been evaluated. Lo Loestrin Fe is a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by women to prevent pregnancy ( 1 ) The efficacy of Lo Loestrin Fe in women with a body mass index of > 35 kg/m 2 has not been evaluated ( 1 , 8.8 )
Mechanism: CHCs prevent pregnancy primarily by suppressing ovulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 21, 2010 Original approval · Type 3 - New Dosage Form ReviewSummary ReviewPediatric Medical Review
1 products under this application
- LO LOESTRIN FE · ETHINYL ESTRADIOL 0.01MG,0.01MG; NORETHINDRONE ACETATE 1MG,N/A · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
- Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00413062 · 2,281 participants · Start Jun 2006 · Primary completion Aug 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral ContraceptivePivotal-lookingCompleted
Duramed ResearchIndustry
NCT00196326 · 2,235 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: DR-1011 · For: Contraception
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00511199 · 2,152 participants · Start May 1, 2006 · Primary completion Apr 1, 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery SystemPivotal-lookingCompleted
Agile TherapeuticsIndustry
NCT02158572 · 2,032 participants · Start Aug 2014 · Primary completion Nov 2016
Drug: AG200-15 · For: Healthy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use373
- amenorrhoea220
- nausea200
- headache163
- drug ineffective158
- metrorrhagia156
- anxiety147
- fatigue139
- depression121
- menstruation irregular108
- product dose omission issue107
- dizziness104
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 4 |
| 2011 | 12 |
| 2012 | 45 |
| 2013 | 28 |
| 2014 | 50 |
| 2015 | 246 |
| 2016 | 437 |
| 2017 | 254 |
| 2018 | 367 |
| 2019 | 366 |
| 2020 | 327 |
| 2021 | 218 |
| 2022 | 212 |
| 2023 | 224 |
| 2024 | 157 |
| 2025 | 167 |
| 2026 | 109 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lo Loestrin Fe (Norethindrone-E.Estradiol-Iron)
2024 spending
$1.3M
Beneficiaries
1,069
3,780 claims
Per beneficiary
$1,207
$6.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $960,598 |
| 2021 | $999,310 |
| 2022 | $1,108,219 |
| 2023 | $1,231,948 |
| 2024 | $1,290,356 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis.
Forslund M, Melin J, Alesi S, et al. · Eur J Endocrinol 2023 · Meta-Analysis, Systematic Review
- Clinical trial of an oral contraceptive containing desogestrel and ethinyl estradiol.
Weijers MJ · Clin Ther 1982 · Clinical Trial
- Comparative evaluation of low-level light therapy and ethinyl estradiol and desogestrel combined oral contraceptive for clinical efficacy and regulation of serum biochemical parameters in primary dysmenorrhoea: a prospective randomised multicentre trial.
Zhu S, Ma X, Ding X, et al. · Lasers Med Sci 2022 · Multicenter Study, Randomized Controlled Trial
- A randomized single-blind non-inferiority trial of delayed start with drospirenone-only and ethinyl estradiol-gestodene pills for ovulation inhibition.
Ratanasaengsuang A, Uaamnuichai S, Santibenchakul S, et al. · Sci Rep 2024 · Randomized Controlled Trial
- Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial.
Weber-Diehl F, Unger R, Lachnit U · Contraception 1992 · Clinical Trial, Multicenter Study
- Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S, Jongwutiwes T, Lertvikool S, et al. · J Obstet Gynaecol Res 2015 · Comparative Study, Randomized Controlled Trial
Sponsor: Apil
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.